HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Promise Of A New Day For Rx-To-OTC Switch Ruled 2012 In “The Tan Sheet”

This article was originally published in The Tan Sheet

Executive Summary

The most popular stories in “The Tan Sheet” during 2012 dealt with FDA’s nonprescription safe use regulatory extension initiative, as well as planned switches by Pfizer and Merck. In dietary supplements, coverage of firms struggling with GMPs and congressional threats to DSHEA drew the most interest.


Related Content

OTC Monographs Face Obsolescence In Shadow Of NDA Products
Oxytrol Switch Should Hinge On Symptom ID, Not Diagnosis – Merck Consultant
Nexium OTC Switch Would Face Crowded Field, Potential Questions
Pfizer Positions For First-In-Class Nasal Corticosteroid Switch
Sponsors Should Hang Tight On “New Paradigm” Switch – CDER’s Leonard-Segal
Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
FDA Pressure Likely In Novartis OTC Plant Shutdown, Recalls
FDA Will Take GMP Inspections To The Next Level
Consumerlab.com & echinacea


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts